» Articles » PMID: 24204944

The Natural Product Magnolol As a Lead Structure for the Development of Potent Cannabinoid Receptor Agonists

Overview
Journal PLoS One
Date 2013 Nov 9
PMID 24204944
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Magnolol (4-allyl-2-(5-allyl-2-hydroxyphenyl)phenol), the main bioactive constituent of the medicinal plant Magnolia officinalis, and its main metabolite tetrahydromagnolol were recently found to activate cannabinoid (CB) receptors. We now investigated the structure-activity relationships of (tetrahydro)magnolol analogs with variations of the alkyl chains and the phenolic groups and could considerably improve potency. Among the most potent compounds were the dual CB1/CB2 full agonist 2-(2-methoxy-5-propyl-phenyl)-4-hexylphenol (61a, K(i) CB1:0.00957 µM; K(i) CB2:0.0238 µM), and the CB2-selective partial agonist 2-(2-hydroxy-5-propylphenyl)-4-pentylphenol (60, K(i) CB1:0.362 µM; K(i ) CB2:0.0371 µM), which showed high selectivity versus GPR18 and GPR55. Compound 61b, an isomer of 61a, was the most potent GPR55 antagonist with an IC50 value of 3.25 µM but was non-selective. The relatively simple structures, which possess no stereocenters, are easily accessible in a four- to five-step synthetic procedure from common starting materials. The central reaction step is the well-elaborated Suzuki-Miyaura cross-coupling reaction, which is suitable for a combinatorial chemistry approach. The scaffold is versatile and may be fine-tuned to obtain a broad range of receptor affinities, selectivities and efficacies.

Citing Articles

Pharmacology of Non-Psychoactive Phytocannabinoids and Their Potential for Treatment of Cardiometabolic Disease.

Wainwright C, Walsh S Handb Exp Pharmacol. 2024; 287():61-93.

PMID: 39235486 DOI: 10.1007/164_2024_731.


Magnolol derivatives as specific and noncytotoxic inhibitors of breast cancer resistance protein (BCRP/ABCG2).

da Silva Zanzarini I, Henrique Kita D, Scheiffer G, Karoline Dos Santos K, de Paula Dutra J, Augusto Pastore M Bioorg Chem. 2024; 146:107283.

PMID: 38513324 PMC: 11069345. DOI: 10.1016/j.bioorg.2024.107283.


An integrated in vitro human iPSCs-derived neuron and in vivo animal approach for preclinical screening of anti-seizure compounds.

Zhao C, Rollo B, Shahid Javaid M, Huang Z, He W, Xu H J Adv Res. 2023; 64:249-262.

PMID: 37995945 PMC: 11464642. DOI: 10.1016/j.jare.2023.11.022.


Efficiency and Mechanism Evaluation of Water Extract in Preventing Gastric Ulcer.

Shen K, Chang C, Hsieh M, Chaung H Evid Based Complement Alternat Med. 2023; 2023:7901734.

PMID: 37064946 PMC: 10101745. DOI: 10.1155/2023/7901734.


Structure-Based Virtual Screening and Molecular Dynamics Simulation Assessments of Depsidones as Possible Selective Cannabinoid Receptor Type 2 Agonists.

Mohamed G, Omar A, AlKharboush D, Fallatah M, Sindi I, El-Agamy D Molecules. 2023; 28(4).

PMID: 36838749 PMC: 9965315. DOI: 10.3390/molecules28041761.


References
1.
Mechoulam R, Parker L . The endocannabinoid system and the brain. Annu Rev Psychol. 2012; 64:21-47. DOI: 10.1146/annurev-psych-113011-143739. View

2.
Felder C, Joyce K, Briley E, Glass M, Mackie K, Fahey K . LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther. 1998; 284(1):291-7. View

3.
Pertwee R . Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997; 74(2):129-80. DOI: 10.1016/s0163-7258(97)82001-3. View

4.
Hanus L, Mechoulam R . Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem. 2010; 17(14):1341-59. DOI: 10.2174/092986710790980096. View

5.
Sharir H, Abood M . Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther. 2010; 126(3):301-13. PMC: 2874616. DOI: 10.1016/j.pharmthera.2010.02.004. View